Table 2.
Univariate and multiple Cox regression analysis to compare the impact of pre-specified patient groups and the exploratory biomarkers at baseline on the progression-free survival. The number next to each group indicates the quantity of patients included within the corresponding analysis.
| Variable | Subgroup | Univariate | Multiple | ||||
|---|---|---|---|---|---|---|---|
| Pat. | HR (95%CI) | p-Value | Pat. | HR (95%CI) | p-Value | ||
| age | <65 years | 31 | 1 | 0.004 | 18 | 1 | 0.002 |
| ≥65 years | 32 | 0.45 (0.26–0.78) | 20 | 0.31 (0.14–0.66) | |||
| gender | male | 48 | - | 0.149 | - | - | - |
| female | 15 | - | - | - | |||
| BMI | ≤25 kg/m² | 22 | 1 | 0.042 | 12 | 1 | 0.008 |
| >25 kg/m² | 41 | 0.57 (0.33–0.98) | 26 | 0.34 (0.15–0.76) | |||
| IMDC risk groups | fav.+ interm. | 47 | 1 | 0.029 | 30 | - | 0.779 |
| poor | 11 | 2.16 (1.08–4.3) | 8 | - | |||
| TSP-2 C1D1 | >665 ppb | 22 | 1 | 0.007 | 19 | 1 | 0.008 |
| ≤665 ppb | 19 | 0.40 (0.20–0.78) | 19 | 0.36 (0.16–0.76) | |||
95% CI: 95% confidence interval; BMI: Body mass index; HR: Hazard ratio; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium TSP-2: Thrombospondin 2; pat.: Patients.